Dear colleagues,

Metabolic disorders, including diabetes mellitus, obesity, and metabolic syndrome, represent a growing global health challenge, characterized by complex pathophysiology and significant clinical burden. Despite advances in conventional therapeutics, limitations such as poor bioavailability, systemic side effects, and suboptimal targeted delivery of treatments persist. In recent years, nanotechnology has emerged as a transformative approach to overcome these challenges by enhancing the therapeutic potential of plant-derived bioactive compounds.

Phytocompounds, known for their insulin-sensitizing, anti-inflammatory, and antioxidant properties, have shown promise in managing metabolic disorders. However, their clinical application has often been hindered by poor solubility, instability in biological environments, and low bioavailability. Nanotechnology-based drug delivery systems—such as liposomes, nanoemulsions, polymeric nanoparticles, and solid lipid nanoparticles—offer innovative solutions to these issues. By encapsulating phytochemicals like curcumin, berberine, quercetin, resveratrol, and naringenin into nanosystems, researchers have achieved enhanced stability, targeted action, and improved pharmacokinetics. These advancements have demonstrated efficacy in reducing oxidative stress, insulin resistance, chronic inflammation, and lipid imbalances in vitro, in vivo and computational studies.

This special issue aims to explore the latest developments in nanotechnology-based phytocompounds for the treatment of metabolic disorders. It invites original research articles, reviews, and case studies focusing on:

· The design and synthesis of novel nanoformulations for phytocompounds.

· Mechanistic insights into how nanosystems improve drug delivery and therapeutic outcomes.

· Clinical trials assessing the safety and efficacy of plant-based nanoformulations.

· Applications of nanomedicine in addressing complications associated with metabolic syndrome.

· Computational studies such as Artificial Intelligence, simulation, dynamic, in silico and meta-analysis for phytocompounds 

By fostering interdisciplinary collaboration between experts in nanotechnology, pharmacology, and metabolic disease management, this special issue seeks to advance the field toward sustainable and effective therapeutic solutions for metabolic disorders. Researchers are encouraged to contribute their findings to shape the future of nanomedicine in this critical domain. We welcome a diversity of articles, such as conceptual and empirical articles, reviews, critical comments, and meta-analyses, for submission to this Special Issue. We will accept manuscripts from different disciplines, addressing topics related to the scope.

- Nanotechnology

- Phytocompounds

- Metabolic disorders

- Diabetes mellitus

- Obesity

- Metabolic syndrome

- Nano drug delivery systems

- Plant-based nanosystems

- Liposomes

- Nanoemulsions

- Solid lipid nanoparticles

- Core-shell nanoparticles

- Hydrogel nanocomposites

- Insulin resistance

- Oxidative stress reduction

- Anti-inflammatory properties

- Antioxidant properties

- Bioavailability enhancement

- Targeted drug delivery

- Green synthesis of nanoparticles

- Medicinal plants and phytochemicals

- Clinical applications of nanomedicine

- Computational studies

- Artificial Intelligence

- Simulation, dynamic

- In silico

- Meta-analysis